↓ Skip to main content

Dove Medical Press

Article Metrics

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

Overview of attention for article published in The Application of Clinical Genetics, July 2017
Altmetric Badge

Mentioned by

45 news outlets
2 tweeters
1 Redditor


12 Dimensions

Readers on

46 Mendeley
Treating <em>EGFR </em>mutation resistance in non-small cell lung cancer &ndash;&nbsp;role of osimertinib
Published in
The Application of Clinical Genetics, July 2017
DOI 10.2147/tacg.s103471
Pubmed ID

Valentina Mazza, Federico Cappuzzo


The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR-mutant non-small cell lung cancer (NSCLC), a particular group of patients with different clinical characteristics and outcome to EGFR-wild-type patients. In these patients, the treatment of choice as first-line therapy is first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, or afatinib. Inevitably, after the initial response, all patients become refractory to these drugs. The most common mechanism of acquired resistance to EGFR-TKIs is the development of a second mutation in exon 20 of EGFR (T790M). Osimertinib is a third-generation EGFR-TKI designed for overcoming T790M-mediated resistance. Based on the results of efficacy and tolerability of Phase II and Phase III studies, osimertinib has been approved for treatment of advanced EGFR(T790M+) mutation NSCLC following progression on a prior EGFR-TKI. Occurrence of acquired resistance to osimertinib represents an urgent need for additional strategies including combination with other agents, such as other targeted therapies or checkpoint inhibitors, or development of new and more potent compounds.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 12 26%
Student > Bachelor 8 17%
Researcher 8 17%
Other 5 11%
Student > Master 3 7%
Other 10 22%
Readers by discipline Count As %
Medicine and Dentistry 14 30%
Unspecified 12 26%
Biochemistry, Genetics and Molecular Biology 8 17%
Pharmacology, Toxicology and Pharmaceutical Science 6 13%
Chemistry 2 4%
Other 4 9%